申请人:SmithKline Beecham, p.l.c.
公开号:US06277861B1
公开(公告)日:2001-08-21
Compounds of formula (I) and pharmaceutically acceptable salts thereof, where R1 is hydrogen, C1-6alkyl (optionally substituted by hydroxy or C1-4alkoxy), C1-6alkenyl, C1-6alkynyl, C1-6alkylCO—, formyl, CF3CO— or C1-6alkylSO2—; R2 is hydrogen or up to three substituents selected from halogen, NO2, CN, N3, CF3O—, CF3S—, CF3CO—, trifluoromethyldiazirinyl, C 1-6?alkyl, C1-6alkenyl, C1-6alkynyl, C1-6perfluoroalkyl, C3-6cycloalkyl, C3-6cycloalkyl-C1-4alkyl-, C1-6alkylO—, C1-6alkylCO—, C3-6cycloalkylO—, C3-6cycloalkylCO—, C3-6cycloalkyl-C1-4alkylO—, C3-6cycloalkyl-C1-4alkylCO—, phenyl, phenoxy, benzyloxy, benzoyl, phenyl-C1-4alkyl-, C1-6alkylS—, C1-6alkylSO2—, (C1-4alkyl)2NSO2—, (C1-4alkyl)NHSO2—, (C1-4alkyl)2NCO—, (C1-4alkyl)NHCO— or CONH2; or —NR5R6 where R5 is hydrogen or C1-4alkyl, and R6 is hydrogen, C1-4alkyl, formyl, —CO2C1-4alkyl or —COC1-4alkyl; or two R2 groups together form a carbocyclic ring that is saturated or unsaturated and unsubstituted or substituted by —OH or ═O; and the two R3 groups and the two R4 groups are each independently hydrogen or C1-6alkyl or the two R3 groups and/or the two R4 groups together form a C3-6spiroalkyl group provided that at least one R3 and R4 group is not hydrogen, are useful in the treatment and prophylaxis of epilepsy and other disorders.
式(I)的化合物及其药学上可接受的盐,其中R1是氢、C1-6烷基(可选择地被羟基或C1-4烷氧基取代)、C1-6烯基、C1-6炔基、C1-6烷基CO—、甲酰基、CF3CO—或C1-6烷基SO2—;R2是氢或来自卤素、NO2、CN、N3、CF3O—、CF3S—、CF3CO—、三氟甲基二氮杂环丙基、C1-6烷基、C1-6烯基、C1-6炔基、C1-6全氟烷基、C3-6环烷基、C3-6环烷基-C1-4烷基、C1-6烷基O—、C1-6烷基CO—、C3-6环烷基O—、C3-6环烷基CO—、C3-6环烷基-C1-4烷基O—、C3-6环烷基-C1-4烷基CO—、苯基、苯氧基、苄氧基、苯甲酰基、苯基-C1-4烷基、C1-6烷基硫—、C1-6烷基SO2—、(C1-4烷基)2NSO2—、(C1-4烷基)NHSO2—、(C1-4烷基)2NCO—、(C1-4烷基)NHCO—或CONH2;或—NR5R6,其中R5是氢或C1-4烷基,R6是氢、C1-4烷基、甲酰基、—CO2C1-4烷基或—COC1-4烷基;或两个R2基共同形成饱和或不饱和的碳环,未取代或被—OH或═O取代;两个R3基和两个R4基各自独立地是氢或C1-6烷基,或两个R3基和/或两个R4基共同形成C3-6螺环烷基,前提是至少一个R3基和R4基不是氢,对癫痫和其他疾病的治疗和预防具有用处。